Mucormycosis during COVID-19 era:A retrospective assessment  

作　　者：Tuhin Mukherjee Tanisha Das Sourav Basak Satyajit Mohanty Krishnendu Adhikary Prity Chatterjee Rajkumar Maiti Prithviraj Karak 

机构地区：[1]Department of Advanced Pharmacology,Birla Institute of Technology,Mesra,Ranchi 835215,Jharkhand,India [2]School of Pharmaceutical Sciences(SPS),Siksha’O’Anusandhan University,Bhubaneswar 751003,Odisha,India [3]Department of Pharmacy,Guru Ghasidas Central University,Bilaspur 495009,Chhattisgarh,India [4]Department of Interdisciplinary Science,Centurion University of Technology&Management,Odisha 761211,India [5]Department of Biotechnology,Paramedical College Durgapur,West Bengal 713212,India [6]Department of Physiology,Bankura Christian College,Bankura,West Bengal 722101,India

出　　处：《Infectious Medicine》2024年第2期10-23,共14页感染医学（英文）

摘　　要：In a retrospective view,this review examines the impact of mucormycosis on health workers and researchers during the COVID era.The diagnostic and treatment challenges arising from unestablished underlying pathology and limited case studies add strain to healthcare systems.Mucormycosis,caused by environmental molds,poses a significant threat to COVID-19 patients,particularly those with comorbidities and compromised immune systems.Due to a variety of infectious Mucorales causes and regionally related risk factors,the disease’s inci-dence is rising globally.Data on mucormycosis remains scarce in many countries,highlighting the urgent need for more extensive research on its epidemiology and prevalence.This review explores the associations between COVID-19 disease and mucormycosis pathology,shedding light on potential future diagnostic techniques based on the fungal agent’s biochemical components.Medications used in ICUs and for life support in ventilated patients have been reported,revealing the challenge of managing this dual onslaught.To develop more effective treatment strategies,it is crucial to identify novel pharmacological targets through“pragmatic”multicenter trials and registries.In the absence of positive mycology culture data,early clinical detection,prompt treatment,and tissue biopsy are essential to confirm the specific morphologic features of the fungal agent.This review delves into the history,pathogens,and pathogenesis of mucormycosis,its opportunistic nature in COVID or immunocompromised individuals,and the latest advancements in therapeutics.Additionally,it offers a forward-looking perspective on potential pharmacological targets for future drug development.

关 键 词：COVID-19 MUCORMYCOSIS Fungal agents PANDEMIC 

分 类 号：R563.1[医药卫生—呼吸系统]